WO2001020018A3 - Diagnosing and treating arthritic disorders - Google Patents

Diagnosing and treating arthritic disorders Download PDF

Info

Publication number
WO2001020018A3
WO2001020018A3 PCT/US2000/025317 US0025317W WO0120018A3 WO 2001020018 A3 WO2001020018 A3 WO 2001020018A3 US 0025317 W US0025317 W US 0025317W WO 0120018 A3 WO0120018 A3 WO 0120018A3
Authority
WO
WIPO (PCT)
Prior art keywords
mitochondrial
indicators
altered
methods
function
Prior art date
Application number
PCT/US2000/025317
Other languages
French (fr)
Other versions
WO2001020018A8 (en
WO2001020018A2 (en
Inventor
Anne N Murphy
James A Dykens
Soumitra S Ghosh
Robert E Davis
Andrew E Granston Jr
Robert Terkeltaub
Original Assignee
Mitokor
Anne N Murphy
James A Dykens
Soumitra S Ghosh
Robert E Davis
Andrew E Granston Jr
Robert Terkeltaub
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor, Anne N Murphy, James A Dykens, Soumitra S Ghosh, Robert E Davis, Andrew E Granston Jr, Robert Terkeltaub filed Critical Mitokor
Priority to AU75826/00A priority Critical patent/AU7582600A/en
Priority to DE60027762T priority patent/DE60027762D1/en
Priority to EP00965038A priority patent/EP1236044B1/en
Priority to CA002384855A priority patent/CA2384855A1/en
Priority to JP2001523789A priority patent/JP2003520575A/en
Publication of WO2001020018A2 publication Critical patent/WO2001020018A2/en
Publication of WO2001020018A8 publication Critical patent/WO2001020018A8/en
Publication of WO2001020018A3 publication Critical patent/WO2001020018A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.
PCT/US2000/025317 1999-09-15 2000-09-15 Diagnosing and treating arthritic disorders WO2001020018A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU75826/00A AU7582600A (en) 1999-09-15 2000-09-15 Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
DE60027762T DE60027762D1 (en) 1999-09-15 2000-09-15 DIAGNOSIS AND TREATMENT OF ARTHRITICAL DISEASES
EP00965038A EP1236044B1 (en) 1999-09-15 2000-09-15 Diagnosing and treating arthritic disorders
CA002384855A CA2384855A1 (en) 1999-09-15 2000-09-15 Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
JP2001523789A JP2003520575A (en) 1999-09-15 2000-09-15 Methods and compositions for diagnosing and treating arthritis disorders and modulating bone mass

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15414599P 1999-09-15 1999-09-15
US60/154,145 1999-09-15
US09/661,848 US7005274B1 (en) 1999-09-15 2000-09-14 Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
US09/661,848 2000-09-14

Publications (3)

Publication Number Publication Date
WO2001020018A2 WO2001020018A2 (en) 2001-03-22
WO2001020018A8 WO2001020018A8 (en) 2001-09-20
WO2001020018A3 true WO2001020018A3 (en) 2002-07-11

Family

ID=26851189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025317 WO2001020018A2 (en) 1999-09-15 2000-09-15 Diagnosing and treating arthritic disorders

Country Status (7)

Country Link
US (2) US7005274B1 (en)
EP (1) EP1236044B1 (en)
JP (1) JP2003520575A (en)
AT (1) ATE325343T1 (en)
CA (1) CA2384855A1 (en)
DE (1) DE60027762D1 (en)
WO (1) WO2001020018A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121335A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents associated with host versus graft and graft versus host rejections
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
AU2002332560B2 (en) * 2001-08-15 2006-01-19 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
EP1578399A4 (en) 2002-12-06 2007-11-28 Isis Pharmaceuticals Inc Methods for rapid identification of pathogens in humans and animals
JP2004331653A (en) * 2003-04-14 2004-11-25 Mitsubishi Pharma Corp Prophylactic and/or remedial agent for pain
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
MXPA06008293A (en) 2004-01-22 2007-06-11 Univ Miami Topical co-enzyme q10 formulations and methods of use.
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
ES2641832T3 (en) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by setting digital thresholds
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
EP1802333A2 (en) 2004-09-13 2007-07-04 Arrowsmith Technologies LLP Antibody buffering of a ligand in vivo
CA2600184A1 (en) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
JP2009502137A (en) 2005-07-21 2009-01-29 アイシス ファーマシューティカルズ インコーポレイティッド Method for rapid identification and quantification of nucleic acid variants
WO2007035397A1 (en) * 2005-09-15 2007-03-29 The Regents Of The University Of Michigan Method and system for measuring cartilage condition biomarkers
CA2977089A1 (en) * 2006-05-02 2007-11-15 University Of Miami Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
ITMI20061375A1 (en) * 2006-07-14 2008-01-15 Fabio Conteduca SYNTHETIC MAINTENANCE WITH REDUCED OXIDABILITY AND RELATIVE PREPARATION PROCESS
WO2008143627A2 (en) 2006-09-14 2008-11-27 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US8821496B2 (en) 2006-09-29 2014-09-02 DePuy Synthes Products, LLC Osteotomy protective cover
US20080167277A1 (en) * 2006-12-29 2008-07-10 Charles Conrad Methods of treating skin disorders with caffeic acid analogs
EP2126132B1 (en) 2007-02-23 2013-03-20 Ibis Biosciences, Inc. Methods for rapid foresnsic dna analysis
EP2155904A2 (en) 2007-05-01 2010-02-24 Hill's Pet Nutrition Inc. Methods and compositions for diagnosing osteoarthritis in a feline
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
CA2703158C (en) * 2007-10-24 2016-11-15 Mochida Pharmaceutical Co. Ltd. Composition for treatment of joint disease
JP5241255B2 (en) * 2008-02-01 2013-07-17 生化学工業株式会社 Evaluation method of joint pain
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
JP6058263B2 (en) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー Methods and uses for inducing apoptosis in cancer cells
EP2123775A1 (en) * 2008-05-20 2009-11-25 Stiftung Tierärztliche Hochschule Hannover Analysis for the genetic disposition for hip dysplasia in Canidae
US8367637B2 (en) * 2008-08-19 2013-02-05 Mochida Pharmaceutical Co., Ltd. Composition for treating arthritic disorder
EP2349549B1 (en) 2008-09-16 2012-07-18 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, and system
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
EP2347254A2 (en) 2008-09-16 2011-07-27 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US8055334B2 (en) * 2008-12-11 2011-11-08 Proteus Biomedical, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
US8263069B2 (en) * 2008-12-31 2012-09-11 Johnson Lanny L Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions
JP2012516995A (en) 2009-02-02 2012-07-26 ネステク ソシエテ アノニム Method for diagnosing impending joint failure
WO2010093943A1 (en) 2009-02-12 2010-08-19 Ibis Biosciences, Inc. Ionization probe assemblies
AU2010247750B2 (en) 2009-05-11 2016-09-22 Berg Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
US20110306516A1 (en) * 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
US9492448B2 (en) 2012-06-20 2016-11-15 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
JP6645737B2 (en) * 2012-09-05 2020-02-14 漂太 高松 Biomarkers for autoimmune diseases
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
US9968623B2 (en) 2013-08-29 2018-05-15 Lanny Leo Johnson Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent
CN105705162A (en) 2013-09-04 2016-06-22 博格有限责任公司 Methods of treatment of cancer by continuous infusion of coenzyme q10
US20160095837A1 (en) * 2014-10-07 2016-04-07 University Of Iowa Research Foundation Modulation of mitochondrial calcium uniporter activity for treating and preventing arrhythmias
AU2018269377A1 (en) 2017-05-17 2019-12-19 Berg Llc Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
JP2022531832A (en) * 2019-05-17 2022-07-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Mitochondrial respiration measurement in frozen specimens
CN110517776B (en) * 2019-08-16 2023-06-16 四川大学华西医院 Old people health risk assessment method and application thereof
TWI789724B (en) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 Use of mitochondria for treatment and/or prevention of tendon damage or related diseases
WO2023073392A1 (en) * 2021-10-29 2023-05-04 Genodx Biomarkers and uses therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870210A (en) * 1987-12-18 1989-09-26 American Home Products Corporation Aminoguanidine derivative as anti-inflammatory agents
EP0745850A1 (en) * 1994-02-19 1996-12-04 Seikagaku Corporation Method of assaying normal aglycan, assaying kit, and method of judging joint-related information
US5935796A (en) * 1995-06-30 1999-08-10 The University Of Melbourne Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
WO2000006150A1 (en) * 1998-07-28 2000-02-10 Synergen Ag Use of creatine compounds for treatment of bone or cartilage cells and tissues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5840493A (en) 1994-03-30 1998-11-24 Mitokor Mitochondrial DNA mutations that segregate with late onset diabetes mellitus
US5888498A (en) 1995-03-03 1999-03-30 Mitokor Cellular and animal models for diseases associated with mitochondrial defects
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5656450A (en) 1994-05-27 1997-08-12 Board Of Regents, The University Of Texas System Activation of latent transforming growth factor β by matrix vesicles
US5932459A (en) 1995-10-20 1999-08-03 Sittinger; Michael Artificial tissues, methods for the production and the use thereof
US5928945A (en) 1996-11-20 1999-07-27 Advanced Tissue Sciences, Inc. Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
AU2474399A (en) 1998-01-26 1999-08-09 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870210A (en) * 1987-12-18 1989-09-26 American Home Products Corporation Aminoguanidine derivative as anti-inflammatory agents
EP0745850A1 (en) * 1994-02-19 1996-12-04 Seikagaku Corporation Method of assaying normal aglycan, assaying kit, and method of judging joint-related information
US5935796A (en) * 1995-06-30 1999-08-10 The University Of Melbourne Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
WO2000006150A1 (en) * 1998-07-28 2000-02-10 Synergen Ag Use of creatine compounds for treatment of bone or cartilage cells and tissues

Non-Patent Citations (43)

* Cited by examiner, † Cited by third party
Title
ALI S Y: "APATITE-TYPE CRYSTAL DEPOSITION IN ARTHRITIC CARTILAGE", SCANNING ELECTRON MICROSCOPY, CHICAGO, IL, US, no. 4, 1985, pages 1555 - 1566, XP001025737 *
ALTMAN F P: "A METABOLIC DYSFUNCTION IN EARLY MURINE OSTEOARTHRITIS", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 40, 1981, pages 303 - 306, XP001023827, ISSN: 0003-4967 *
BAGINSKI T J ET AL: "THE ROLE OF HYDROXYL RADICALS IN RODENT MODELS OF ARTHRITIS", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 11, no. 3, 1997, pages A332, XP001016256, ISSN: 0892-6638 *
BAYNES J W ET AL: "ROLE OF OXIDATIVE STRESS IN DIABETIC COMPLICATIONS A NEW PERSPECTIVE ON AN OLD PARADIGM", DIABETES, NEW YORK, NY, US, vol. 48, no. 1, January 1999 (1999-01-01), pages 1 - 9, XP001023927, ISSN: 0012-1797 *
BOOS N ET AL: "IMMUNOHISTOCHEMICAL ANALYSIS OF TYPE X-COLLAGEN EXPRESSION IN OSTEOARTHRITIS OF THE HIP JOINT", JOURNAL OF ORTHOPAEDIC RESEARCH, THE JOURNAL OF BONE AND JOINT SURGERY, INC.,, US, vol. 17, no. 4, July 1999 (1999-07-01), pages 495 - 502, XP001023670, ISSN: 0736-0266 *
CENCETTI A ET AL: "SUPEROXIDE ANION PRODUCTION BY CIRCULATING POLYMORPHONUCLEAR LEUCOCYTES IN RHEUMATOID ARTHRITIS", CLINICAL RHEUMATOLOGY, ACTA MEDICA BELGICA, BRUXELLES, BE, vol. 9, no. 1, 1990, pages 51 - 55, XP001023925, ISSN: 0770-3198 *
CHAPMAN M L ET AL: "INCREASED CARBONYL CONTENT OF PROTEINS IN SYNOVIAL FLUID FROM PATIENTS WITH RHEUMATOID ARTHRITIS", JOURNAL OF RHEUMATOLOGY, TORONTO, CA, vol. 16, no. 1, 1989, pages 15 - 18, XP001023926, ISSN: 0315-162X *
CHEUNG H S ET AL: "SPECIFIC INHIBITION OF BASIC CALCIUM PHOSPHATE AND CALCIUM PYROPHOSPHATE CRYSTAL-INDUCTION OF METALLOPROTEINASE SYNTHESIS BY PHOSPHOCITRATE", BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1315, no. 2, 1996, pages 105 - 111, XP001023752, ISSN: 0006-3002 *
CHICHESTER C O ET AL: "Immunological detection of type II collagen degradation: Use in the evaluation of anti-arthritis therapies.", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 48, no. 7, 1996, pages 694 - 698, XP000991040, ISSN: 0022-3573 *
CORVO M LUISA ET AL: "Intravenous administration of superoxide dismutase entrapped in long circulating liposomes: II. In vivo fate in a rat model of adjuvant arthritis.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1419, no. 2, 15 July 1999 (1999-07-15), pages 325 - 334, XP000991006, ISSN: 0006-3002 *
CUSH J J ET AL: "US CONSENSUS GUIDELINES FOR THE USE OF CYCLOSPORIN A IN RHEUMATOID ARTHRITIS", JOURNAL OF RHEUMATOLOGY, TORONTO, CA, vol. 26, no. 5, May 1999 (1999-05-01), pages 1176 - 1186, XP001023934, ISSN: 0315-162X *
DOYLE D V: "TISSUE CALCIFICATION AND INFLAMMATION IN OSTEOARTHRITIS", JOURNAL OF PATHOLOGY, CHICHESTER, SUSSEX, GB, vol. 136, no. 3, 1982, pages 199 - 216, XP001023749, ISSN: 0022-3417 *
GALLERON S ET AL: "Reactive oxygen species induce apoptosis of synoviocytes in vitro. alpha-Tocopherol provides no protection.", CELL BIOLOGY INTERNATIONAL., vol. 23, no. 9, 1999, pages 637 - 642, XP000991538, ISSN: 1065-6995 *
GLANSBEEK H L ET AL: "STIMULATION OF ARTICULAR CARTILAGE REPAIR IN ESTABLISHED ARTHRITIS BY LOCAL ADMINISTRATION OF TRANSFORMING GROWTH FACTOR-BETA INTO MURINE KNEE JOINTS", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 78, no. 2, February 1998 (1998-02-01), pages 133 - 142, XP001023703, ISSN: 0023-6837 *
GRIFFEY R H ET AL: "DEPLETION OF HIGH-ENERGY PHOSPHATES IN THE CENTRAL NERVOUS SYSTEM OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, AS DETERMINED BY PHOSPHORUS-31 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 33, no. 6, June 1990 (1990-06-01), pages 827 - 833, XP001023597, ISSN: 0004-3591 *
HASSAN M Q ET AL: "PROTECTIVE EFFECTS OF ANTIOXIDANTS AGAINST RHEUMATOID ARTHRITIS-INDUCED LIPID PEROXIDATION AND GLUTATHIONE DEPLETION", RESEARCH COMMUNICATIONS IN PHARMACOLOGY AND TOXICOLOGY, PJD PUBLICATIONS, WESTBURY, NY, US, vol. 3, no. 3/4, 1998, pages 105 - 113, XP001029924, ISSN: 1087-1101 *
ISHII TAKAO ET AL: "Effect of growth factors and cytokines on experimentally-induced osteoarthritic chondrocytes.", NIHON UNIVERSITY JOURNAL OF MEDICINE, vol. 40, no. 5, October 1998 (1998-10-01), pages 245 - 255, XP001025735, ISSN: 0546-0352 *
JOHNSON K ET AL: "MATRIX VESICLE PLASMA CELL MEMBRANE GLYCOPROTEIN-1 REGULATES MINERALIZATION BY MURINE OSTEOBLASTIC MC3T3 CELLS", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 14, no. 6, June 1999 (1999-06-01), pages 883 - 892, XP001023751, ISSN: 0884-0431 *
JOHNSON K ET AL: "MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION IA A DOWNSTREAM REGULATOR OF NITRIC OXIDE EFFECTS ON CHONDROCYTE MATRIX SYNTHESIS AND MINERALIZATION", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 43, no. 7, July 2000 (2000-07-01), pages 1560 - 1570, XP001023837, ISSN: 0004-3591 *
JOHNSON KRISTEN ET AL: "Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes.", ARTHRITIS & RHEUMATISM, vol. 42, no. 9, 1999, pages 1986 - 1997, XP000991044, ISSN: 0004-3591 *
KAPLAN R ET AL: "PROPRANOLOL AND THE TREATMENT OF RHEUMATOID ARTHRITIS", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 23, no. 2, February 1980 (1980-02-01), pages 253 - 255, XP001023936, ISSN: 0004-3591 *
LAFEBER F P J G ET AL: "TRANSFORMING GROWTH FACTOR-BETA PREDOMINANTLY STIMULATES PHENOTYPICALLY CHANGED CHONDROCYTES IN OSTEOARTHRITIC HUMAN CARTILAGE", JOURNAL OF RHEUMATOLOGY, TORONTO, CA, vol. 24, no. 3, 1997, pages 536 - 542, XP001023704, ISSN: 0315-162X *
LUNEC J ET AL: "A MARKER OF OXIDATIVE DNA DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 348, no. 2, 1994, pages 131 - 138, XP001016255, ISSN: 0014-5793 *
MARINELLO E ET AL: "THE PURINE NUCLEOTIDE CONTENT OF LYMPHOCYTES FROM PATIENTS WITH RHEUMATOID ARTHRITIS", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, BIOSCIENCE EDIPRINT, GENEVA,, CH, vol. 14, no. 2, 1994, pages 57 - 63, XP001023619, ISSN: 0251-1649 *
MARK VON DER K ET AL: "TYPE X COLLAGEN SYNTHESIS IN HUMAN OSTEOARTHRITIC CARTILAGE INDICATION OF CHONDROCYTE HYPERTROPHY", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 35, no. 7, July 1992 (1992-07-01), pages 806 - 811, XP001023714, ISSN: 0004-3591 *
MEYDANI M ET AL: "URINARY 8-OHDG AS A MARKER OF OXIDATIVE STRESS IN RHEUMATOID ARTHRITIS (RA) AND AGING: EFFECT OF PROGRESSIVE RESISTANCE TRAINING(PRT)", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 11, no. 3, 1997, pages A377, XP001016257, ISSN: 0892-6638 *
MIYATA T ET AL: "INCREASED PENTOSIDINE, AN ADVANCED GLYCATION END PRODUCT, IN PLASMAAND SYNOVIAL FLUID FROM PATIENTS WITH RHEUMATOID ARTRITIS AND ITS RELATION WITH INFLAMMATORY MARKERS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 244, no. 1, 6 March 1998 (1998-03-06), pages 45 - 49, XP001023765, ISSN: 0006-291X *
NORDEMAR R ET AL: "MUSCLE ATP CONTENT IN RHEUMATOID ARTHRITIS - A BIOPSY STUDY", SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 34, no. 2, 1974, pages 185 - 191, XP001023595, ISSN: 0085-591X *
PALMOSKI M J ET AL: "MARKED SUPPRESSION BY SALICYLATE OF THE AUGMENTED PROTEO GLYCAN SYNTHESIS IN OSTEO ARTHRITIC CARTILAGE", ARTHRITIS AND RHEUMATISM, vol. 23, no. 1, 1980, pages 83 - 91, XP000991404, ISSN: 0004-3591 *
PRATTA M A ET AL: "EFFECT OF EBSELEN ON IL-1-INDUCED ALTERATIONS IN CARTILAGE METABOLISM", INFLAMMATION RESEARCH, BIRKHAEUSER VERLAG, BASEL, CH, vol. 47, no. 3, 1998, pages 115 - 121, XP000852928, ISSN: 1023-3830 *
PULLIG O ET AL: "Metabolic activation of chondrocytes in human osteoarthritis - Expression of type II collagen.", ZEITSCHRIFT FUER ORTHOPAEDIE UND IHRE GRENZGEBIETE, vol. 137, no. 1, January 1999 (1999-01-01), pages 67 - 75, XP000991048, ISSN: 0044-3220 *
REDISKE J ET AL: "NITRIC OXIDE AND OSTEOARTHRITIS: PATHWAYS OF PROTEIN NITROS-YLATIONIN CHONDROCYTES", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 40, no. 9, SUPPL, September 1997 (1997-09-01), pages S184, XP001023931, ISSN: 0004-3591 *
ROSEN FRED ET AL: "Differential effects of aging on human chondrocyte responses to transforming growth factor beta: Increased pyrophosphate production and decreased cell proliferation.", ARTHRITIS & RHEUMATISM, vol. 40, no. 7, 1997, pages 1275 - 1281, XP000991022, ISSN: 0004-3591 *
ROSENTHAL A K: "CALCIUM CRYSTAL-ASSOCIATED ARTHRITIDES", CURRENT OPINION IN RHEUMATOLOGY, CURRENT SCIENCE, LONDON, GB, vol. 10, no. 3, May 1998 (1998-05-01), pages 273 - 277, XP001023750, ISSN: 1040-8711 *
RUSH G F ET AL: "THE MECHANISM OF ACUTE CYTOTOXICITY OF TRIETHYLPHOSPHINE GOLD(I) COMPLEXES II. TRIETHYLPHOSPHINE GOLD CHLORIDE-INDUCED ALTERATIONS IN MITOCHONDRIAL FUNCTION", TOXICOLOGY AND APPLIED PHARMACOLOGY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 90, no. 3, 1987, pages 391 - 400, XP001023935 *
SAULEDA J ET AL: "THE ACTIVITY OF CYTOCHROME OXIDASE IS INCREASED IN CIRCULATING LYMPHOCYTES OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE,ASTHMA AND CHRONIC ARTHRITIS", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 161, no. 1, January 2000 (2000-01-01), pages 32 - 35, XP001023839, ISSN: 1073-449X *
TANKA D ET AL: "ELECTRON TRANSPORTING ENZYMES OF RHEUMATOID CONNECTIVE TISSUE", ACTA MORPHOLOGICA ACADEMIAE SCIENTIARUM HUNGARICAE, vol. 25, no. 2-3, 1977, E, pages 137 - 146, XP001023838, ISSN: 0001-6217 *
TANKA D ET AL: "ROLE OF MITOCHONDRIAL ENZYMES IN THE PATHOMECHANISM OF RHEUMATOID ARTHRITIS", ACTA BIOCHIMICA ET BIOPHYSICA ACADEMIAE SCIENTIARUM HUNGARICAE, vol. 19, no. 1-2, 1984, pages 116, XP001023933, ISSN: 0001-5253 *
TERKELTAUB ROBERT ET AL: "Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1: Relevance to calcium pyrophosphate dihydrate deposition disea", ARTHRITIS & RHEUMATISM, vol. 37, no. 6, 1994, pages 934 - 941, XP000991051, ISSN: 0004-3591 *
TOMITA M ET AL: "NITRIC OXIDE REGULATES MITOCHONDRIAL RESPIRATION AND FUNCTIONS OF ARTICULAR CHONDROCYTES", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 44, no. 1, January 2001 (2001-01-01), pages 96 - 104, XP001023828, ISSN: 0004-3591 *
VAN BEUNINGEN HENK M ET AL: "Transforming growth factor-beta-1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint.", LABORATORY INVESTIGATION, vol. 71, no. 2, 1994, pages 279 - 290, XP000991038, ISSN: 0023-6837 *
WILLER B ET AL: "EFFECTS OF CREATINE SUPPLEMENTATION ON MUSCLE WEAKNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 39, no. 3, March 2000 (2000-03-01), pages 293 - 298, XP001023937, ISSN: 1462-0324 *
YAMADA E ET AL: "DIFFERENTIAL DISPLAY ANALYSIS OF MURINE COLLAGEN-INDUCED ARTHITIS: CLONING OF THE CDNA-ENCODING MURINE ATPASE INHIBITOR", IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 92, no. 4, December 1997 (1997-12-01), pages 571 - 576, XP001016129, ISSN: 0019-2805 *

Also Published As

Publication number Publication date
EP1236044B1 (en) 2006-05-03
DE60027762D1 (en) 2006-06-08
ATE325343T1 (en) 2006-06-15
US20070021496A1 (en) 2007-01-25
US7005274B1 (en) 2006-02-28
EP1236044A2 (en) 2002-09-04
WO2001020018A8 (en) 2001-09-20
JP2003520575A (en) 2003-07-08
CA2384855A1 (en) 2001-03-22
WO2001020018A2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
WO2001020018A8 (en) Diagnosing and treating arthritic disorders
WO2000066762A3 (en) Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
DE59611341D1 (en) USE OF SACCHARIDE CONJUGATES
WO2002099048A3 (en) LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
NO994932L (en) Mixtures and Methods for Treating and Diagnosing Breast Cancer
MXPA02012032A (en) Diagnostic methods for pompe disease and other glycogen storage diseases.
EP1423133A4 (en) Treatment of muscular dystrophies and related disorders
EP1163515A4 (en) Therapeutic and diagnostic tools for impaired glucose tolerance conditions
WO2006078853A3 (en) Thioredoxin interacting protein (txnip) as regulator of vascular function
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
AU5596998A (en) Pyk2 related products and methods
BR9906926A (en) Compositions and methods for treating cells having double minute dna
WO2004007531A3 (en) Activated checkpoint therapy and methods of use thereof
WO2002090925A3 (en) Polypeptides and nucleic acids associated with cancer
CA2069611A1 (en) Method to Detect Bone and Other Connective Tissue Disorders in Humans and Animals
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
ATE395433T1 (en) SCREENING PROCESS FOR SUITABLE ACTIVE INGREDIENTS
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
EP1254260A4 (en) Methods for diagnosing and treating heart disease
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
WO2001049879A3 (en) Methods for comparing gene expression levels or patterns in normal or tumor cells
EP1255110A3 (en) Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
AU4654097A (en) Rdgb-proteins
WO2003028536A3 (en) Methods for diagnosing and treating heart disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 12/2001 UNDER (30) REPLACE "NOT FURNISHED" BY "09/661848"

WWE Wipo information: entry into national phase

Ref document number: 2384855

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 523789

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000965038

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000965038

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000965038

Country of ref document: EP